Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
171 hedge funds and large institutions have $2.3B invested in Acceleron Pharma in 2019 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 74 increasing their positions, 45 reducing their positions, and 18 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 45
56% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 18
19% more capital invested
Capital invested by funds: $1.93B → $2.3B (+$367M)
15% more call options, than puts
Call options by funds: $17.5M | Put options by funds: $15.2M
6% more funds holding
Funds holding: 162 → 171 (+9)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$64.5M |
| 2 |
AG
Artal Group
Luxembourg
|
+$26.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.5M |
| 4 |
Alkeon Capital Management
New York
|
+$20.6M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$39.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$22.8M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$15.3M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.9M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$9.75M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Neuberger Berman Group
New York
| – | -$1.05M | -24,075 | Closed |
|
177
Ameriprise
Minneapolis,
Minnesota
| – | -$1M | -23,004 | Closed |
|
|
AR
178
Advisory Research
Chicago,
Illinois
| – | -$783K | -17,988 | Closed |
|
|
NTC
179
NF Trinity Capital
Central,
Hong Kong
| – | -$626K | -14,369 | Closed |
|
|
BG
180
Bellevue Group
Kuesnacht,
Switzerland
| – | -$623K | -14,300 | Closed |
|
181
AQR Capital Management
Greenwich,
Connecticut
| – | -$403K | -9,255 | Closed |
|
|
CI
182
Cowen Inc
New York
| – | -$236K | -5,411 | Closed |
|
|
CWG
183
C WorldWide Group
Copenhagen,
Denmark
| – | -$224K | -5,146 | Closed |
|
|
RJFSA
184
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$223K | -5,111 | Closed |
|
|
MNBTD
185
Moody National Bank Trust Division
Galveston,
Texas
| – | -$6K | -128 | Closed |
|
|
AP
186
Arlington Partners
Birmingham,
Alabama
| – | -$3K | -62 | Closed |
|
|
SFSIG
187
San Francisco Sentry Investment Group
San Francisco,
California
| – | -$1K | -18 | Closed |
|
XLRN Hedge Fund Activity: Q1 2019 in Review
171 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q1 2019, worth a combined $2.3B — up 19% from $1.93B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new XLRN positions and 18 closed out — a net gain of 10 holders — while 74 added to existing stakes and 45 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $64.5M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $39.9M sold.
- 171 institutional investors held Acceleron Pharma (XLRN) as of Q1 2019, up from 162 in Q4 2018.
- Funds reported $2.3B of Acceleron Pharma stock for Q1 2019, up 19% quarter-over-quarter.
- 28 funds opened new Acceleron Pharma positions in Q1 2019 and 18 closed out, a net change of +10 holders.
- The largest Acceleron Pharma buyer in Q1 2019 was Wellington Management Group, an estimated $64.5M added.
- The largest Acceleron Pharma seller in Q1 2019 was Perceptive Advisors, an estimated $39.9M sold.
Based on aggregated 13F filings for Q1 2019.